Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.
Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.
复制标题
在博茨瓦纳（Botswana）的基于Dolutegravir的抗逆转录病毒疗法上经历的治疗中，有四类耐药的HIV-1亚型C经验丰富的个体。
DOI：
10.1097/qad.0000000000001920
复制
发表时间：
2018-08-24
期刊：
影响因子：
--
通讯作者：
Gaseitsiwe S
中科院分区：
文献类型：
--
作者：
Seatla KK;Avalos A;Moyo S;Mine M;Diphoko T;Mosepele M;Gaolatlhe T;Rowley CF;Ramaabya D;Jarvis JN;Kasvosve I;Gaseitsiwe S
在艾滋病毒-1 C亚型占主导地位的南部非洲，关于基于dolutegravir（DTG）的联合抗逆转录病毒疗法（ART）在现实生活中的有效性的数据有限。我们报告了一名感染HIV-1亚型C的患者，该患者既往接受过雷特格韦治疗，并对四种抗逆转录病毒药物产生了多药耐药突变。有必要进行耐药性监测和临床警戒，以确保艾滋病毒治疗计划的有效性，即使在基于DTG的ART时代。
There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings in southern Africa where HIV-1 subtype C predominates. We report a patient infected with HIV-1 subtype C on DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations to four antiretroviral classes. There is need for drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment programs even in the era of DTG-based ART.